BVAXF (BioVaxys Technology) Change In Receivables : $-0.07 Mil (TTM As of Jul. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Change In Receivables?

BioVaxys Technology's change in receivables for the quarter that ended in Jul. 2024 was $-0.03 Mil. It means BioVaxys Technology's Accounts Receivable increased by $0.03 Mil from Apr. 2024 to Jul. 2024 .

BioVaxys Technology's change in receivables for the fiscal year that ended in Oct. 2023 was $-0.03 Mil. It means BioVaxys Technology's Accounts Receivable increased by $0.03 Mil from Oct. 2022 to Oct. 2023 .

BioVaxys Technology's Accounts Receivable for the quarter that ended in Jul. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BioVaxys Technology's liquidation value for the three months ended in Jul. 2024 was $-1.58 Mil.

BioVaxys Technology Change In Receivables Historical Data

The historical data trend for BioVaxys Technology's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Change In Receivables Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Change In Receivables

Get a 7-Day Free Trial

-0.04

-0.03

BioVaxys Technology Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Change In Receivables	Get a 7-Day Free Trial															-0.01	-0.01	-0.01	-0.03	-0.03

BioVaxys Technology Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.07 Mil.

BioVaxys Technology (OTCPK:BVAXF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

BioVaxys Technology's Days Sales Outstanding for the quarter that ended in Jul. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, BioVaxys Technology's accounts receivable are only considered to be worth 75% of book value:

BioVaxys Technology's liquidation value for the quarter that ended in Jul. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.358	-	1.937	+	0.75 * 0	+	0.5 * 0
=	-1.58

BioVaxys Technology Change In Receivables Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.